Ceribell, Inc. (CBLL) Form 10-Q — Nov 3, 2026
Ceribell reported Q3 2026 revenue of $29.3 million, up 30% year over year, with nine-month revenue of $83.9 million, up 31%. Gross margin reached 90% in the quarter, up 2 points, aided by tariff refunds of $1.6 million and unit cost reductions. Net loss widened 59% to $21.4 million in the quarter ($60.4 million for nine months) as operating expenses grew 36%, driven by headcount expansion and $6.7 million of nine-month legal costs tied to its patent infringement suit against Natus Medical. The company held $117.5 million in cash and marketable securities and said this funds operations for at least the next 12 months.
Key figures
- Revenue
- 29341000
- Total Debt
- 20000000
- Revenue Yoy
- 30% (Q3 2026 vs Q3 2025); 31% for nine months
- Total Assets
- 156370000
- Cash Position
- 41989000
- Shares Outstanding
- 38835010
- Employees
- over 380
- Q3 gross margin
- 90%
- Hospitals adopted
- more than 700
- Nine month revenue
- 83933000
- Accumulated deficit
- 280712000
- Ieepa tariff refund
- 1600000
- Loss on debt extinguishment
- 1500000
- Stock based comp nine month
- 16820000
- Cash plus marketable securities
- 117500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.